BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
Bank of America Merrill Lynch initiates Aurobindo Pharma with buy
Potential of a turnaround with re-rating. US to drive 34 per cent revenue during FY13-16E CAGR. Profitability improving as balance sheet strengthens. Target Rs 425.